Emergence of Macrolide-Resistant <i>Mycoplasma pneumoniae</i> with a 23S rRNA Gene Mutation

DOI DOI Web Site PubMed 29 Citations Open Access
  • Miyuki Morozumi
    Laboratory of Infectious Agents Surveillance, Kitasato Institute for Life Sciences, Kitasato University, 5-9-1 Shirokane, Minatoku, Tokyo, Japan
  • Keiko Hasegawa
    Laboratory of Infectious Agents Surveillance, Kitasato Institute for Life Sciences, Kitasato University, 5-9-1 Shirokane, Minatoku, Tokyo, Japan
  • Reiko Kobayashi
    Laboratory of Infectious Agents Surveillance, Kitasato Institute for Life Sciences, Kitasato University, 5-9-1 Shirokane, Minatoku, Tokyo, Japan
  • Nagako Inoue
    Kitasato Institute for Life Sciences & Graduate School of Infection Control Sciences, Kitasato University, Tokyo, Japan
  • Satoshi Iwata
    National Hospital Organization Tokyo Medical Center, Tokyo, Japan
  • Haruo Kuroki
    Medical Corporation Nagatsu-kai Saito Hospital, Chiba, Japan
  • Naohisa Kawamura
    Osaka Rosai Hospital, Osaka, Japan
  • Eiichi Nakayama
    Hakujikai Memorial Hospital, Tokyo, Japan
  • Takeshi Tajima
    Hakujikai Memorial Hospital, Tokyo, Japan
  • Kouichi Shimizu
    Saiseikai Ibaraki Hospital, Osaka, Japan
  • Kimiko Ubukata
    Laboratory of Infectious Agents Surveillance, Kitasato Institute for Life Sciences, Kitasato University, 5-9-1 Shirokane, Minatoku, Tokyo, Japan

Search this article

Description

<jats:title>ABSTRACT</jats:title> <jats:p> A total of 195 <jats:italic>Mycoplasma pneumoniae</jats:italic> strains were isolated from 2,462 clinical specimens collected between April 2002 and March 2004 from pediatric outpatients with respiratory tract infections. Susceptibilities to six macrolide antibiotics (ML), telithromycin, minocycline, levofloxacin, and sitafloxacin were determined by the microdilution method using PPLO broth. A total of 183 <jats:italic>M. pneumoniae</jats:italic> isolates were susceptible to all agents and had excellent MIC <jats:sub>90</jats:sub> s in the following order: 0.00195 μg/ml for azithromycin and telithromycin, 0.0078 μg/ml for clarithromycin, 0.0156 μg/ml for erythromycin, 0.0625 μg/ml for sitafloxacin, 0.5 μg/ml for minocycline, and 1 μg/ml for levofloxacin. Notably, 12 ML-resistant <jats:italic>M. pneumoniae</jats:italic> strains were isolated from patients with pneumonia (10 strains) or acute bronchitis (2 strains). These strains showed resistance to ML with MICs of ≥1 μg/ml, except to rokitamycin. Transition mutations of A2063G or A2064G, which correspond to A2058 and A2059 in <jats:italic>Escherichia coli</jats:italic> , in domain V on the 23S rRNA gene in 11 ML-resistant strains were identified. By pulsed-field gel electrophoresis typing, these strains were classified into groups I and Vb, as described previously (A. Cousin-Allery, A. Charron, B. D. Barbeyrac, G. Fremy, J. S. Jensen, H. Renaudin, and C. Bebear, Epidemiol. Infect. <jats:bold>124:</jats:bold> 103-111, 2000). These findings suggest that excessive usage of MLs acts as a trigger to select mutations on the corresponding 23S rRNA gene with the resultant occurrence of ML-resistant <jats:italic>M. pneumoniae</jats:italic> . Monitoring ML susceptibilities for <jats:italic>M. pneumoniae</jats:italic> is necessary in the future. </jats:p>

Journal

Citations (29)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top